Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27751810 | 0.89 | POLB (0.53) | POLBCYP2C9CYP2C19FFAR2KMT2A | |
| SCHEMBL6405250 | 0.86 | POLB (0.50) | POLBCYP2C9CYP2C19KMT2AMMP2 | |
| SCHEMBL12500447 | 0.86 | POLB (0.50) | POLBCYP2C9CYP2C19KMT2AMMP2 | |
| SCHEMBL951695 | 0.86 | POLB (0.50) | POLBCYP2C9CYP2C19KMT2AMMP2 | |
| SCHEMBL9577449 | 0.86 | FFAR2 (0.49) | POLBCYP2C9CYP2C19FFAR2KMT2A | |
| SCHEMBL27438873 | 0.85 | FFAR2 (0.51) | POLBCYP2C9CYP2C19FFAR2KMT2A | |
| SCHEMBL1742115 | 0.85 | POLB (0.58) | POLBCYP2C9CYP2C19FFAR2KMT2A | |
| SCHEMBL7711076 | 0.85 | POLB (0.58) | POLBCYP2C9CYP2C19FFAR2KMT2A | |
| SCHEMBL16075922 | 0.85 | POLB (0.58) | POLBCYP2C9CYP2C19FFAR2KMT2A | |
| SCHEMBL491605 | 0.84 | MMP2 (0.52) | POLBCYP2C9CYP2C19FFAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4253935-A | — | — | None | — | — | JP | disclosed |
| CN-103384661-A | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME | 2013-11-06 | — | — | CN | disclosed |
| US-6914122-B2 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION (US) | 2005-07-05 | — | — | US | disclosed |
| CN-1441806-A | Macrocyclic NS 3-serine protease inhibitors of hepatitis C virus comprising an N-ring P2 moiety | SCHERING CORP (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1274724-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING ALKYL AND ARYL ALANINE P2 MOIETIES | SCHERING CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION | 2002-02-07 | — | — | US | disclosed |
| WO-2001081325-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING ALKYL AND ARYL ALANINE P2 MOIETIES | SCHERING CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| JP-H04253935-A | PRODUCTION OF 2-(4-CHLORPHENYL)-3-METHYLBUTYRIC ACID | HOECHST AG | 1992-09-09 | — | — | JP | disclosed |
| EP-0312124-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-19 | — | — | EP | disclosed |
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | PRSS3, HPN, DPP3 | POLB 4387/4885CYP2C9 1693/4885CYP2C19 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.